BioTissue Reported Phase 2 Dry Eye Study Results
The Miami-based firm presented data on its TTAX03 therapy at the American Academy of Ophthalmology meeting.
Updated on Oct. 10, 2026 in Biotech
Live Poll
Do you trust medical treatments developed from human birth tissue to be safe and effective?
Miami-based BioTissue has announced positive Phase 2 clinical study results for its investigational dry eye therapy, TTAX03. The company presented the findings at the American Academy of Ophthalmology Annual Meeting.
Why it matters
The study aims to address persistent dry eye symptoms, with researchers looking to establish effective dosing regimens. Future research remains necessary to fully confirm efficacy and safety protocols.
The randomized study included 74 patients treated with TTAX03 or saline over 5 days. Researchers evaluated outcomes against a control group to measure safety and symptom improvement through 12 weeks.
The players
BioTissue
A Miami-based company that develops regenerative therapies and clinical ocular treatments.
American Academy of Ophthalmology
An organization hosting its annual meeting to review developments in eye care and research.
The details
The double-masked, multicenter study randomized participants in a 1:1:1:1 ratio. The highest dose group demonstrated the most significant symptom improvement and higher rates of corneal staining resolution. Researchers measured changes in best-corrected visual acuity at Day 85, noting no serious adverse events related to the treatment.
Timeline
October 9, 2026: BioTissue announced the Phase 2 study results.
October 9-12, 2026: The company presented data at the American Academy of Ophthalmology meeting in New Orleans.
Day 85: Researchers measured changes in best-corrected visual acuity.
Beyond the 305
The study follows the rigorous multi-phase clinical trial requirements established by the FDA for new medical therapies. These results represent a preliminary finding in the path toward potential regulatory review and future market approval.
Patients with chronic dry eye in the local community may eventually see this therapy as a treatment option if future trials prove successful. Continued clinical research will be needed to determine when and how this product might reach the public.
The takeaway
BioTissue demonstrated the safety of its TTAX03 therapy in an early-stage study. Local observers should watch for future announcements regarding the timeline for phase three trials and eventual regulatory filings.
Further reading
For more on the latest local scientific developments, visit our Biotech section.
More information
View the full American Academy of Ophthalmology conference program for details on the presented study.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust medical treatments developed from human birth tissue to be safe and effective?
